Qlaris Bio
Dedham, MA · Biotechnology · 10 employees
Qlaris is advancing QLS-111, a novel topical ocular therapy designed to lower intraocular pressure through a unique mechanism of action. Unlike current treatments, QLS-111 selectively targets episcleral venous pressure (EVP) and enhances outflow distal to the trabecular meshwork. This innovative approach may offer improved treatment options for conditions in which EVP is limited or pathological
Funding history
- Funding Round — $5.6M — Nov 2025
- Funding Round — $24.0M — Apr 2024
- Funding Round — $8.2M — Aug 2019
Recent signals
- Mar 10, 2026: Qlaris Bio Appoints Fred Guerard as President and Chief Executive Officer
- Nov 17, 2025: Raised $5.6M
- Apr 22, 2024: Raised $24.0M
- Aug 28, 2019: Raised $8.2M
See plans & pricing → Track Qlaris Bio’s funding, hiring, and signals — with verified contacts — on Fundz.